Mealey's (August 16, 2022, 10:57 AM EDT) -- CHICAGO — An Illinois federal judge overseeing the testosterone replacement therapy multidistrict litigation on Aug. 6 denied a plaintiff’s motion for a new trial, finding that defendant Actavis Inc. did not impermissibly introduce a warning label for a different drug or hold back a relevant Food and Drug Administration letter....